Cancer Supportive Care Products Market: By Cancer (Lung Cancer, Liver Cancer, Breast Cancer, Leukemia, Prostate Cancer, Ovarian Cancer, Bladder Cancer), By Therapeutic Area (Oral Mucositis And Dry Mouth, Chemotherapy Induced Nausea And Vomiting Cancer Pain, Chemotherapy Induced Anemia, Chemotherapy Induced Neutropenia, Bone Metastases), ByDistriution Channel (Hospital Pharmacies, Retail Pharmacies, Compounding Pharmacies) By Geography

 

Cancer Supportive Care Products Market size was valued at USD 21,834.5 million in 2021 and is expected to grow at a CAGR of 2.5% from 2022 to 2028. The global market provides a detailed overview and which can be segmented by cancer, therapeutic area, distribution channel, and region. By cancer, the cancer supportive care products market has been segmented into lung cancer, liver cancer, breast cancer, leukemia, prostate cancer, ovarian cancer, and bladder cancer. By cancer, the breast cancer segment held the largest revenue share of the gastric cancer therapy market in past years and is expected to have a significant growth rate over the forecasted period due to increasing incidences of breast cancer majorly in women worldwide. By therapeutic area, the cancer supportive care products market has been segmented into oral mucositis and dry mouth, chemotherapy-induced nausea and vomiting cancer pain, chemotherapy-induced anemia, chemotherapy-induced neutropenia, and bone metastases. By therapeutic area, the chemotherapy-induced nausea and vomiting cancer pain segment held the largest revenue share of the gastric cancer therapy market in past years and is expected to have the fastest growth rate over the forecasted period. By distribution channel, the cancer supportive care products market has been segmented into hospital pharmacies, retail pharmacies, and compounding pharmacies. By distribution channel, the retail pharmacies segment held the largest revenue share of the gastric cancer therapy market in past years and is expected to have the fastest growth rate over the forecasted period due to the high demand for cancer care products. Key Development: In August 2020, in a late-stage study, Bristol Myers Squibb stated that Idhifa, which has been approved by the FDA for relapsed or refractory AML with an IDH2 mutation, failed to show efficacy in improving survival in the same patient population when given alongside optimum supportive treatment. In September 2020, Merck presented more than 30 abstracts at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.